Reliance Matrix, a Workday Software Alliance partner, is proud to be a Signature Sponsor of the upcoming Workday Rising 2023 in San Francisco, California.
Workday Rising is a top forum to connect with customers and partners worldwide, and explore how Workday is putting artificial intelligence (AI) and machine learning (ML) to work in powerful, responsible ways.
Reliance Matrix VP of Total Rewards & HR Operations, Shera Chase, will present during the "Workday in Insurance" session on Wednesday, September 27 to discuss measurable efficiencies created through human capital management (HCM) transformation and three must-take steps to ensure success.
While at Workday Rising, don't miss the opportunity to connect with other Reliance Matrix leaders through:
Demos: Stop by the Reliance Matrix booth on the exhibit floor to learn more about how Reliance Matrix can support all facets of absence and employee benefit administration as an integrated solution.
1:1 sessions: Meet with our Chief Solutions Officer, Gordon Smith, and Chief Marketing Officer, Patrick Trinsey, to learn about our roadmap and upcoming enhancements. Contact us to request a meeting.
Reliance Matrix, a leader in absence and employee benefits, is a trusted Workday Software Alliance partner, specializing in creating meaningful efficiencies and enhanced customer experience for employers that sponsor employee benefits and/or outsource absence administration with the company.
The Workday Rising conference will be held at the Moscone Center in San Francisco, Calif., September 26-29, 2023. For more information about Workday Rising, visit https://rising.workday.com/us.html.
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Enterprises in Asia Pacific are moving toward software-defined networking (SDN) to make communication more secure and resilient and speed up business decision-making, according to a new research report published today by Information Services Group...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...